Search Medical Condition
Please enter condition
Please choose location from dropdown

Springfield, Massachusetts Clinical Trials

A listing of Springfield, Massachusetts clinical trials actively recruiting patient volunteers.

RESULTS

Found (116) clinical trials

International PFO Consortium

Background The prevalence of patent foramen ovale (PFO) is about 25% in the general population and approximately 40% in patients who have ischemic stroke of unknown cause (cryptogenic stroke). Given the large number of asymptomatic patients, no primary prevention is currently recommended. On the contrary, secondary prevention is very important. ...

Phase N/A

1.5 miles

Learn More »

CA-IX p16 Proliferative Markers and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

PRIMARY OBJECTIVES: I. To examine CA-IX, p16, Ki-67, and mini-chromosome maintenance complex component 2 (MCM2) expression in liquid-based cytology (LBC) specimens to see which subset of markers can provide the optimal diagnosis of significant cervical lesions in women in North America with a cytologic diagnosis of atypical glandular cells (AGC) ...

Phase N/A

1.5 miles

Learn More »

Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

OBJECTIVES: - To provide a mechanism for sample collection and submission for diagnostic review to determine eligibility of patients with suspected leukemia or related hematologic disorders for enrollment on ECOG leukemia clinical trials. - To obtain baseline samples for correlative studies outlined in parent clinical trials. OUTLINE: This is a ...

Phase N/A

1.5 miles

Learn More »

Study of Kidney Tumors in Younger Patients

PRIMARY OBJECTIVES: I. Classify patients with renal tumors by histological categorization, surgico-pathological stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity for chromosomes 1p and 16q, to define eligibility for a series of therapeutic studies. (Loss of heterozygosity [LOH] testing discontinued as of April 2014) II. ...

Phase N/A

1.5 miles

Learn More »

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

PRIMARY OBJECTIVES: I. To prospectively analyze the factors that are currently used for risk-group assignment (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog [MYCN] copy number by fluorescent in situ hybridization [FISH], deoxyribonucleic acid [DNA] content by flow cytometry, and tumor histology using the International Neuroblastoma Pathologic Classification System) in ...

Phase N/A

1.5 miles

Learn More »

fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth

Hologic has developed a quantitative test to assess the amount of fetal fibronectin (fFN) present in cervicovaginal secretions, and evaluate the clinical utility of the test in assessing spontaneous Pre-Term Bith risk in a high risk population. Identifying women at high risk of giving birth prematurely can be challenging. It ...

Phase N/A

1.5 miles

Learn More »

Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 1

This first phase will be a prospective cohort study. We will validate the bedside tool in at least 4 adult and at least 4 pediatric ICUs and if necessary we will modify the bedside tool. The computerized bedside tool will be considered refined if >90% of the generated instructions are ...

Phase

1.5 miles

Learn More »

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

PRIMARY OBJECTIVES: I. To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina. SECONDARY OBJECTIVES: I. To capture the sites of recurrence subsequent to treatment ...

Phase

1.5 miles

Learn More »

Fabry Disease Registry

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com In Europe - +31-35-699-1232, europe@FabryRegistry.com In Latin America - +617-591-5500, help@FabryRegistry.com In North America - +617-591-5500, help@FabryRegistry.com

Phase N/A

1.5 miles

Learn More »

Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives ...

Phase N/A

1.5 miles

Learn More »